Connect with us

Health

Novartis’ New Drug Shows Strong Results Against Malaria, Offering Hope Amid Rising Resistance

Published

on

Swiss pharmaceutical company Novartis has reported promising results for its experimental malaria drug GanLum, saying it will move quickly to seek regulatory approval after a successful late-stage clinical trial. The new treatment has shown strong effectiveness not only against standard malaria strains but also against drug-resistant forms of the parasite, a growing concern in Africa and other parts of the world.

The trial involved nearly 1,700 participants across 12 African countries, comparing GanLum to existing artemisinin-based combination therapy (ACT), which has been the standard treatment for the past two decades. Four weeks after treatment, 85.3 percent of patients who received GanLum had no symptoms or detectable parasites, compared with 82.1 percent in the group that received standard care. Novartis said this translates to a cure rate of 99.2 percent for GanLum versus 96.7 percent for existing therapies.

Dr. Abdoulaye Djimdé, a professor of parasitology and mycology at the University of Science, Techniques and Technologies of Bamako, Mali, described the results as potentially “the biggest advance in malaria treatment for decades.” He noted that “drug resistance is a growing threat to Africa, so new treatment options can’t come a moment too soon.”

Malaria remains one of the world’s most serious infectious diseases. According to the World Health Organization (WHO), there were around 263 million malaria cases and 597,000 deaths globally in 2023, with Africa accounting for the vast majority. Children under five represent about three-quarters of all malaria deaths on the continent.

Current treatments rely mainly on ACT, which combines artemisinin with other drugs. However, resistance to artemisinin has begun to emerge in several African countries, including Rwanda, Uganda, and Eritrea, raising fears that progress against the disease could stall. GanLum’s formula uses two different compounds that attack the malaria parasite through separate biological mechanisms, helping it remain effective even against resistant strains.

See also  Europe Gears Up for Marathon Season as Runners Take to the Streets

Dr. Shreeram Aradhye, president of development and chief medical officer at Novartis, said the new treatment “has the potential to both treat the disease and block transmission.” He added that the company plans to move “as quickly as possible” to submit GanLum for regulatory approval.

The trial focused on patients with acute, uncomplicated malaria caused by Plasmodium falciparum, the most deadly and widespread malaria parasite in Africa. The research was funded partly by the European Union, Germany, and the United Kingdom, and the results were presented this week at a scientific meeting.

Dr. Alena Pance, a senior genetics lecturer at the University of Hertfordshire in the United Kingdom who was not involved in the study, called the findings “really encouraging,” though she urged further testing on severe and cerebral malaria as well as other parasite species.

If approved, GanLum could mark a major milestone in the global fight against malaria, providing a new tool to counter the rise of resistance and potentially saving hundreds of thousands of lives each year.

Health

Congenital Infections Linked to Higher Risks of Autism and Intellectual Disability

Published

on

Children born with certain infections acquired during pregnancy face substantially higher risks of autism and intellectual disability later in life, according to a study of more than 3.7 million people in Sweden.

Researchers found that children with congenital infections were about three times more likely to be diagnosed with autism and more than seven times more likely to receive a diagnosis of intellectual disability than those without such infections.

The findings suggest that infections transmitted from a pregnant woman to her foetus may have lasting effects on brain development, although the study identifies an association rather than proving that the infections directly cause autism or intellectual disability.

The research focused on TORCH infections, a group that includes syphilis, rubella, toxoplasmosis, cytomegalovirus and herpesvirus. These infections can cross the placenta and affect the developing foetus, potentially increasing the risk of miscarriage, stillbirth and other pregnancy complications.

“Although these congenital infections are rare, some of them can be prevented, which makes them important from a public health perspective,” said Reneé Gardner of the Department of Global Public Health at Karolinska Institutet, who contributed to the study.

The researchers examined people born in Sweden between 1987 and 2021 and followed them for up to 30 years. Among the 3.7 million participants, 975 had been diagnosed with a congenital TORCH infection.

Although congenital infections accounted for only a small proportion of autism cases across the population, the risk among affected children was considerably higher. The researchers estimated that about one in five children born with a TORCH infection could later develop autism.

See also  Trainee Doctors Praised for Heroic Response After Deadly Air India Crash in Ahmedabad

The study also found elevated risks of intellectual disability across different levels of severity. The risk of severe to profound intellectual disability was as much as 30 times higher among children with a congenital infection than among those without one.

The researchers found evidence of an impact on educational outcomes even among people who were not diagnosed with autism or intellectual disability. A total of 420 participants with a TORCH infection showed poor school performance without receiving either diagnosis.

Congenital cytomegalovirus, or CMV, is the most common of these infections globally and affects roughly one in 150 newborns. Its burden is substantially greater in low- and middle-income countries.

The researchers said the findings highlight the importance of prevention, particularly in regions where these infections are more common. They pointed to vaccination programmes and other preventive measures as important tools for reducing congenital infections.

They also called for improved identification of affected newborns. Current screening systems, including those used in Sweden, may miss asymptomatic infections because universal screening for TORCH infections is not routinely carried out.

The authors said stronger screening and prevention strategies could help identify children at risk earlier and improve long-term support and care.

Continue Reading

Health

AI Chatbots Make Faster, Less Nuanced Kidney Transplant Decisions Than Doctors

Published

on

Artificial intelligence chatbots may make faster and more confident decisions than human doctors when determining which patient should receive a life-saving kidney transplant, but a new study found that the systems often rely on fewer factors and show less sensitivity to the ethical complexity of such choices.

Researchers from Penn State University in the United States compared decisions made by large language models (LLMs) with choices made by people in earlier studies on kidney allocation. The researchers presented AI models with hypothetical cases based on existing datasets in which human participants had previously chosen between two patients competing for a single available kidney.

The patients were described using characteristics including age, health and drinking habits. Both were considered eligible for the transplant, requiring the decision maker to determine which patient should receive the available organ.

The researchers tested the AI systems in several ways. Some scenarios focused on individual characteristics, while others combined several traits to examine how the models handled competing considerations. In some tests, participants and AI systems were also given the option of flipping a coin, allowing researchers to assess indecision as part of moral decision-making.

Human participants generally placed greater importance on age, often favouring younger patients over older patients. Many of the AI models, however, placed greater weight on lower alcohol consumption.

Hadi Hosseini, the study’s lead researcher at Penn State University, said the findings showed that AI chatbots can diverge from human values when weighing characteristics of patients.

The researchers found that human decisions tended to consider several factors together and were more sensitive to context. LLMs, by contrast, frequently focused on a single characteristic when making their choices.

See also  Poland Urges Polio Vaccinations After Virus Found in Warsaw Sewage

Another difference involved uncertainty. Human participants were more likely to recognise that organ allocation can involve competing ethical considerations and that there may not be one objectively correct answer. AI models generally showed little hesitation and committed to one choice.

John Dickerson, chief executive officer of Mozilla.ai and a collaborator on the study, said humans recognise ambiguity when allocating scarce resources and use debate to shape how such decisions are made.

The findings come as AI systems are increasingly being used in healthcare for clinical workflows, diagnosis, treatment planning and decisions involving limited medical resources.

The researchers said kidney allocation presents a particularly important test because decisions over deceased-donor and living-donor organs involve medical, ethical and moral considerations.

Hosseini said the ethical stakes are high because decisions involving organ allocation can directly affect patients’ lives. He stressed that the study was not intended to encourage replacing professional medical judgment with AI.

Instead, the researchers said understanding how AI systems behave in high-stakes situations is becoming increasingly important as individuals, organisations and businesses use AI to make decisions or provide recommendations.

Continue Reading

Health

Frankfurt Issues Malaria Warning After Six Cases Reported Since July

Published

on

Health authorities in Frankfurt have warned residents and people working near the city’s airport to seek medical advice if they develop an unexplained fever after six malaria cases were reported in the city since July.

Two of the cases have been fatal, while two additional infections have recently been identified in the Schwanheim district, which is located close to Frankfurt Airport. The city’s public health authority is investigating whether the latest cases are connected.

Several of the recent infections have involved airport employees. Authorities suspect that mosquitoes capable of transmitting malaria may occasionally arrive in Germany on aircraft travelling from regions where the disease is widespread. If the insects survive and later bite people, they can potentially transmit the infection.

Malaria is a tropical disease transmitted through the bite of an infected mosquito. It is not normally spread directly from one person to another.

Frankfurt’s health authority said early diagnosis is important because malaria can initially resemble common illnesses such as influenza or a cold. Typical symptoms include fever, chills, headaches, pain in the limbs and gastrointestinal problems.

The Robert Koch Institute has warned that these symptoms can sometimes be mistaken for flu-like illnesses or stomach infections. The most dangerous form of the disease is malaria tropica, caused by the Plasmodium falciparum parasite. Without prompt diagnosis and treatment, it can become life-threatening.

People who live, work or spend significant amounts of time near Frankfurt Airport have been advised to consult a doctor if they develop unexplained fever. They should tell medical staff that they live or have recently spent time in the area around the airport.

See also  Five Years On: COVID-19 Pandemic Leaves Lingering Mysteries and Challenges

The city’s public health authority is also providing information through a telephone hotline, available from 9am to 6pm on 069/212-30030.

Residents can take measures to reduce the risk of mosquito bites by using insect repellents and wearing clothing that covers the skin. Insect nets can also provide protection. Repellents containing DEET or icaridin are among the products recommended by Germany’s Federal Foreign Office.

Cases of so-called airport malaria remain rare in Germany. Research cited by the Robert Koch Institute indicates that more than 99% of malaria cases recorded in Europe are acquired in endemic regions outside the continent.

Between 1969 and early 2024, databases recorded 145 malaria cases in which patients were infected within Europe. More than two-thirds were classified as airport malaria. France recorded 52 cases, Belgium 19 and Germany nine, including eight in Frankfurt and one in Munich.

The two people recently infected in Frankfurt’s Schwanheim district are receiving hospital treatment, according to the city authorities.

The latest cases have prompted renewed attention to the possibility of malaria transmission in areas surrounding international airports, particularly when unexplained fever occurs without a recent trip to a malaria-endemic country.

Continue Reading

Trending